Evidence map›Paper›PMID 40323446›Full record

ArticleCellular and molecular life sciences : CMLS2025

Fibulin-1 deficiency alleviates liver fibrosis by inhibiting hepatic stellate cell activation via the p38 MAPK pathway.

Wenshan Zhao, Jingyu Zhang, Qingdong Guo, Qi Wang, Hong Zhao, Fan Xiao, Ming Han, Ying Cao, Rui Ding, Aiting Yang and 1 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Curcumin Targets Crispld2 to Suppress Hepatic Stellate Cell Activation via PI3K/AKT Pathway Inhibition in Hepatic Fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenshan Zhao *Center of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Jingyu Zhang *Center of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Qingdong GuoDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, People's Republic of China.
Qi WangCenter of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Hong ZhaoCenter of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Fan XiaoInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Ming HanInstitute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Ying CaoCenter of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Rui DingCenter of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Aiting YangExperimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China. yangaiting168@126.com.
Wen XieCenter of Liver Diseases, National Medical Centre for Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China. xiewen6218@163.com.ORCID http://orcid.org/0000-0002-7314-8175

Funding

Beijing Hospitals Authority Innovation Studio of Young Staff Funding 202138Beijing Municipal Administration of Hospitals Incubating Program PX2021066Beijing Municipal Administration of Hospitals Incubating Program PX2024063National Natural Science Foundation of China 81900547
6 · The paper itself

Abstract

Elastin stabilization has been correlated with the reversibility of fibrosis. Fibulin-1 can participate in elastin assembly, which promotes its stabilization. However, the role of Fibulin-1 in liver fibrosis remains unknown. Here, we performed a proteomics analysis to identify notable changes in Fibulin-1 expression during continuous fibrosis progression and regression. Fibulin-1 expression was dramatically increased in the plasma of patients with cirrhosis as well as in liver fibrosis models and hepatic stellate cells (HSCs) treated with TGF-β1, and significant accumulation of Fibulin-1 was observed in chronic hepatitis B (CHB)- and metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis. Functional studies demonstrated that Fibulin-1 silencing inhibited HSC activation, while the opposite effects were observed for Fibulin-1 overexpression in vitro. Furthermore, transcriptomic analysis revealed that Fibulin-1 mediated p38 MAPK pathway activation, which was confirmed by the addition of a p38 MAPK inhibitor. More importantly, Fibulin-1 depletion in a CCl

Indexed as

Calcium-Binding ProteinsHepatic Stellate CellsLiver CirrhosisMAP Kinase Signaling Systemp38 Mitogen-Activated Protein KinasesAnimalsCell LineElastinHumansMaleMiceMice, Inbred C57BLCalcium-Binding ProteinsElastinfibulinp38 Mitogen-Activated Protein KinasesElastinExtracellular matrixFibulin- 1Liver fibrosisRegression

Identifiers

PMID40323446
PMCPMC12052672

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.